4 February 2022 in Cell Metabolism
11 April 2019 in Nature Reviews Molecular Cell Biology
23 November 2020 in Proceedings of the National Academy of Sciences
Significance: This work demonstrates that oncogenic activation of the PI3K-AKT-mTOR signaling pathway suppresses ferroptosis via the sterol regulatory element-binding protein-mediated lipogenesis, and that inhibition of this pathway potentiates the cancer therapeutic effect of ferroptosis induction. This finding unveils mechanisms for the regulation of ferroptosis and provides a potential cancer therapeutic approach for treating cancer patients bearing tumorigenic mutations in the PI3K-AKT-mTOR pathway.
28 October 2015 in Nature
In response to cancer-associated stress, autophagy machinery mediates degradation of nuclear lamina components in mammals, suggesting that cells might degrade nuclear components to prevent tumorigenesis. Much is known about degradation of the cytoplasmic content by the process of autophagy. Shelly Berger and colleagues provide evidence that the nuclear content is also subject to such cellular clearance. The authors show that, in response to cancer-associated stress such as the activated oncogene RAS, the autophagy protein LC3 interacts with the nuclear lamina protein lamin B1 and binds to lamin-associated domains on chromatin. Lamin B1 is then shuttled to the cytoplasm for degradation within lysosomes. Inhibiting this process led to delay in oncogene-induced senescence, hinting that cells might degrade nuclear components to prevent tumorigenesis. Macroautophagy (hereafter referred to as autophagy) is a catabolic membrane trafficking process that degrades a variety of cellular constituents and is associated with human diseases1,2,3. Although extensive studies have focused on autophagic turnover of cytoplasmic materials, little is known about the role of autophagy in degrading nuclear components. Here we report that the autophagy machinery mediates degradation of nuclear lamina components in mammals. The autophagy protein LC3/Atg8, which is involved in autophagy membrane trafficking and substrate delivery4,5,6, is present in the nucleus and directly interacts with the nuclear lamina protein lamin B1, and binds to lamin-associated domains on chromatin. This LC3–lamin B1 interaction does not downregulate lamin B1 during starvation, but mediates its degradation upon oncogenic insults, such as by activated RAS. Lamin B1 degradation is achieved by nucleus-to-cytoplasm transport that delivers lamin B1 to the lysosome. Inhibiting autophagy or the LC3–lamin B1 interaction prevents activated RAS-induced lamin B1 loss and attenuates oncogene-induced senescence in primary human cells. Our study suggests that this new function of autophagy acts as a guarding mechanism protecting cells from tumorigenesis.
2 September 2015 in Nature
A ChIP-seq analysis of the DNA-binding properties of mutant gain-of-function p53 protein compared to wild-type p53 reveals the gain-of-function proteins bind to and activate a distinct set of genes including chromatin modifying enzymes such as the histone methyltransferase MLL; small molecular inhibitors of MLL function may represent a new target for cancers with mutant p53. Wild-type p53 is a tumour suppressor, but mutation of p53 can promote cancer and certain oncogenic forms are gain-of-function (GOF) mutants. Shelley Berger and colleagues compare the genomic binding patterns of wild- type and gain-of-function mutant p53 using ChIP-seq analysis and find that the p53 mutants bind distinct sets of genes compared to the wild-type protein, with key targets including the histone methyltransferases MLL1 and MLL2, as well as other chromatin modifying enzymes. Gain-of-function p53 mutant cells are highly dependent on the MLL pathway for growth and are sensitive to small molecule inhibitors of MLL function, indicating a novel therapeutic avenue for cancers with these p53 mutations. TP53 (which encodes p53 protein) is the most frequently mutated gene among all human cancers. Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a ‘gain-of-function’ (GOF) that promotes cancer. Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation. Analysis of The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF patient-derived tumours, but not in wild-type p53 or p53 null tumours. Cancer cell proliferation is markedly lowered by genetic knockdown of MLL1 or by pharmacological inhibition of the MLL1 methyltransferase complex. Our study reveals a novel chromatin mechanism underlying the progression of tumours with GOF p53, and suggests new possibilities for designing combinatorial chromatin-based therapies for treating individual cancers driven by prevalent GOF p53 mutations.